Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
US stock insider trading | Xenon Pharmaceuticals disclosed one insider transaction on March 13
On March 13, 2026, Xenon Pharmaceuticals (XENE) disclosed an insider trading transaction. Executive KENNEY CHRISTOPHER JOHN sold 1,410 shares on that date.
【Recent Insider Transactions】
【Company Profile】
Xenon Pharmaceuticals Inc., incorporated under the Business Corporations Act (British Columbia) in its predecessor (Xenon Bioresearch Inc.) on November 5, 1996, in British Columbia. The company is a clinical-stage biopharmaceutical company focused on discovering and developing pipeline therapies for orphan diseases. The company plans to commercialize for larger markets and establish partnerships with global pharmaceutical companies. To develop targeted drugs, the company has built a core discovery platform researching rare human diseases with extreme traits, including ion channel mutation diseases, also known as ion channel gene mutation diseases. The company owns an integrated platform that includes human genetics, small molecule drug discovery, and preclinical and clinical development functions.